TITLE

Liposomal Influenza Vaccine

AUTHOR(S)
Holm, K.J.; Goa, K.L.
PUB. DATE
February 1999
SOURCE
BioDrugs;1999, Vol. 11 Issue 2, p137
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
▴ This trivalent liposomal influenza vaccine consists of purified influenza haemagglutinin inserted into a membrane of phosphatidylcholine and phosphatidylethanolamine. It contains 15µg of haemagglutinin per viral strain per dose. ▴ The vaccine is immunogenic in the elderly, in younger adults and in children and adolescents with or without cystic fibrosis. ▴ Seroconversion rates were significantly higher with the liposomal vaccine than with a subunit vaccine for 3 of 3 and 2 of 3 strains in 2 published studies. Seroconversion occurred in a significantly greater number of participants receiving the liposomal vaccine than in those receiving a whole virus vaccine for all 3 strains in 1 study. ▴ Seroprotection rates were significantly better with the liposomal vaccine than with a subunit vaccine for 2 of 3 and 1 of 3 strains in 2 trials, and greater than with a whole virus vaccine for 2 of 3 strains in 1 trial. ▴ In a study in children with cystic fibrosis, a single dose of the liposomal vaccine was reported to have greater immunogenicity than 2 half doses (statistical analysis not performed). ▴ Local adverse reactions such as pain at the injection site, local induration, redness and swelling are transient and usually mild. ▴ Liposomal influenza vaccine did not induce a mean antiphospholipid antibody response in elderly volunteers.
ACCESSION #
9522635

 

Related Articles

  • Quadrivalent flu vaccine discussed. Blazek, Nicole // Infectious Diseases in Children;Mar2009, Vol. 22 Issue 3, p20 

    The article reports that U.S. health officials who attended the meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) have discussed the possibility of developing a quadrivalent influenza vaccine that would extend protection against the Victoria and Yamagata...

  • Universal flu vaccine? Kåhrström, Christina Tobin // Nature Reviews Microbiology;Nov2013, Vol. 11 Issue 11, p740 

    The article reports on a research finding which indicates that the use of virus-specific CD8+T cells in targeting conserved core proteins could be a blueprint for a universal flu vaccine.

  • New type of flu vaccine is quicker to produce.  // Modern Healthcare;11/26/2012, Vol. 42 Issue 48, p4 

    The article announces the approval of a new seasonal influenza vaccine called FluceIvax produced by Novartis Vaccines and Diagnostics by the U.S. Food and Drug Administration (FDA).

  • Drugs, Vaccines, Surveillance for Influenza All Get Boosts. Breindl, Anette // BioWorld Today;7/10/2008, Vol. 19 Issue 133, p1 

    The article reports that calls for improvements in the fight against influenza including the development of vaccine stockpile are being urged by different sectors. These are reactions brought about by statistics showing 250,000 to 500,000 die from the seasonal strains of influenza, and possibly...

  • Drug Roundup.  // RN;May2004, Vol. 67 Issue 5, p85 

    Presents news concerning drug development in the United States as of May 2004. Cases of oligohidrosis and hyperthermia reported in patients taking topiramate tablets or sprinkle capsules; Food and Drug Administration's investigation of reports that unlicensed flu vaccine is being sold in the...

  • Avian flu special: Is this our best shot? Check, Erika // Nature;5/26/2005, Vol. 435 Issue 7041, p404 

    Considers issues hampering efforts to develop a vaccine against pandemic flu. Differences between a pandemic strain that has crossed over from birds and common flu; Problems encountered in clinical trials of flu vaccines; Funding of flu vaccine development.

  • The race to make pandemic vaccine.  // New Scientist;6/20/2009, Vol. 202 Issue 2713, p3 

    The author comments on the article "Swine Flu Vaccine Gets Go Ahead." The author questions how worried should people be now that the World Health Organization (WHO) has decided that the disease is a full-on pandemic. According to the author, the next flu pandemic raises the possibility of a...

  • Flu vaccine makers upgrade technology—and pray for time. Sheridan, Cormac // Nature Biotechnology;Jun2009, Vol. 27 Issue 6, p489 

    The article deals with initiatives of public sector laboratories and biotechnology companies to develop vaccines against the swine-derived influenza A (H1N1) strain detected in Mexico in April 2009. The capacity to develop pandemic vaccines is driven by improvements in the process and...

  • Recommended composition of influenza virus vaccines for use in the 2010 influenza season (southern hemisphere winter).  // Weekly Epidemiological Record;10/9/2009, Vol. 84 Issue 41, p421 

    The article focuses on the recommendation regarding the composition of influenza vaccines for 2010 influenza season. It states that a recommendation for the composition of vaccines will be made in February 2010 that will be used for the influenza winter season in the northern hemisphere. It...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics